Yttrium-90 Radiolabeled Anti-Tac Antibody
Lymphoma, T-Cell, Cutaneous
National Cancer Institute (NCI)radiopharmaceuticalPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
62 Active assets in the Lymphoma, T-Cell, Cutaneous cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-VINCRISTINE Shanghai Jiao Tong University School of Medicine | Phase 4 | BBB |
Cyclophosphamide Shanghai Jiao Tong University School of Medicine | Phase 4 | BBB |
Bexarotene Case Comprehensive Cancer Center | Phase 4 | BBB |
DEXAMETHASONE National Cancer Institute (NCI) | Phase 2 | BBB |
FILGRASTIM City of Hope Medical Center | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Yttrium-90 Radiolabeled Anti-Tac Antibody is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →